Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Bar-Meir

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Human Mutation|March 26, 2003
Genetic analysis of familial colorectal cancer in Israeli ArabsRakefet Chen-Shtoyerman, Livia Theodor, Ester Harmati, et al.
American Journal of Medical Genetics. Part A|August 19, 2003
Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patientsHerma H Fidder, Sylviane Olschwang, Benjamin Avidan, et al.
Diseases of the Colon and Rectum|July 9, 2003
Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditisSimon Bar-Meir, Herma H Fidder, Mark Faszczyk, et al.
Annals of the New York Academy of Sciences|September 18, 2009
Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic roleMerav Lidar, Pnina Langevitz, Ori Barzilai, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2004
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamineWolfgang Kruis, Simon Bar-Meir, Janos Feher, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Gastroenterology|November 13, 2010
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's diseaseAndreas Tromm, Ivan Bunganič, Eva Tomsová, et al.
Journal of Clinical Gastroenterology|July 8, 2005
A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseasesRami Eliakim, Virender K Sharma, Kamel Yassin, et al.
JAMA|April 10, 2008
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled TrialsBrian G Feagan, William J Sandborn, Ulrich Mittmann, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Human Mutation|March 26, 2003
Genetic analysis of familial colorectal cancer in Israeli ArabsRakefet Chen-Shtoyerman, Livia Theodor, Ester Harmati, et al.
American Journal of Medical Genetics. Part A|August 19, 2003
Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patientsHerma H Fidder, Sylviane Olschwang, Benjamin Avidan, et al.
Diseases of the Colon and Rectum|July 9, 2003
Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditisSimon Bar-Meir, Herma H Fidder, Mark Faszczyk, et al.
Annals of the New York Academy of Sciences|September 18, 2009
Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic roleMerav Lidar, Pnina Langevitz, Ori Barzilai, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2004
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamineWolfgang Kruis, Simon Bar-Meir, Janos Feher, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Gastroenterology|November 13, 2010
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's diseaseAndreas Tromm, Ivan Bunganič, Eva Tomsová, et al.
Journal of Clinical Gastroenterology|July 8, 2005
A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseasesRami Eliakim, Virender K Sharma, Kamel Yassin, et al.
JAMA|April 10, 2008
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled TrialsBrian G Feagan, William J Sandborn, Ulrich Mittmann, et al.
Pageof 5